糖心logo

糖心logo raises GBP 5.5 million pre-series A round

17/11/2025

糖心logo Therapeutics presents additional muscle preservation and liver-fat clearance data in obesity at EASD

16/9/2025

糖心logo Therapeutics presents data demonstrating restoration of insulin sensitivity

23/6/2025

糖心logo Therapeutics presents exciting new data showing weight loss with muscle preservation

14/5/2025

糖心logo Therapeutics appoints Xavier Jacq as CSO

1/5/2025

糖心logo Therapeutics Expands Leadership Team with Strategic Appointments

9/1/2025

糖心logo Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity

10/10/2024

糖心logo Strengthens Leadership with Key Appointments as it Reveals Obesity Programme

3/10/2024

Strengthening Scientific Advisory Board with Appointment of Four International Experts

7/3/2024

糖心logo Therapeutics Announces Close of Seed Extension Financing Round

13/12/2023

Announcing Scientific Advisory Board, Chief Development Officer and Finance Director

7/3/2023

糖心logo Therapeutics Announces Seed Financing

25/4/2022

socials

More Updates